A oxigenoterapia hiperbárica no cão e no gato em Portugal
Miniatura indisponível
Data
2020
Título da revista
ISSN da revista
Título do Volume
Editora
Resumo
A oxigenoterapia hiperbárica (OTH) consiste na inalação de uma alta dose (100%) de oxigénio sob condições hiperbáricas, ou seja, dentro de uma câmara hiperbárica e sujeito a uma pressão superior a 1,4 ATA (6psi), sabendo que até valores de 3,0 ATA (29,4psi) é considerada uma terapêutica segura.
O objetivo central deste estudo foi identificar se a OTH provoca efeitos secundários no doente e quais. Deste modo, os efeitos secundários menores e maiores registados ao longo da referida terapia. Este estudo pretendeu ainda registar quais as etiologias com maior e menor prescrição para a OTH e encontrar linhas orientativas de tratamento para as mesmas.
Para tal, recorreu-se a uma amostra populacional de 50 doentes (44 cães e 6 gatos) que foram submetidos à OTH no Centro de Reabilitação e Regeneração Animal de Lisboa.
Os resultados obtidos revelaram que a OTH é uma terapia bem aceite por todos os doentes com 76% dos mesmos a demostrarem apetência para a câmara. Relativamente aos efeitos secundários menores (ESm), as maiores percentagens (42%) referem-se ao ato de bocejar, deglutir e abanar a cabeça. Os efeitos secundários maiores cingiram-se a 2% dos animais que demonstraram sinais de barotrauma, nunca impedindo a realização da terapêutica. Observou-se, ainda, que as etiologias com maior prescrição foram as de origem neurológica (n=29), traumática (n=14) e metabólica (n=7), e que todas beneficiaram do uso de ATA elevadas, com 64% (32/50) da amostra a realizar tratamento com ATA superior a 2,0. Foi ainda comprovado que a média de valores de ATA apresentou uma tendência com significância estatística em relação à idade (p=0,087).
Hyperbaric oxygen therapy (HBOT) consists of inhaling a high dose (100%) of oxygen under hyperbaric conditions, that is, inside a hyperbaric chamber and subject to a pressure greater than 1.4 ATA (6psi), knowing that till values of 3.0 ATA (29.4psi) is considered a safe therapy. The main objective of this study was to identify whether HBOT causes side effects in the patient and which ones. Thus, the minor and major side effects experienced during this therapy. This study also intended to record which etiologies had the highest and lowest prescription for hyperbaric oxygen therapy and to find guidelines for the treatment of these etiologies. To this end, a population sample of 50 patients (44 dogs and 6 cats) who underwent HBOT at the Centro de Reabilitação e Regeneração Animal de Lisboa was used. The results obtained revealed that HBOT is a well-accepted therapy for all patients and that the side effects observed never prevent it from being performed. It was also observed that the etiologies with the highest prescription are those of neurological, traumatic and metabolic origin, and that all benefit more from the use of elevated ATA. The results obtained revealed that HBOT is a well-accepted therapy for all patients, with 76% of them showing acceptance for the chamber. Regarding minor side effects (ESm), the highest percentages (42%) are related to yawning, swallowing and head shaking. The major side effects were limited to 2% of the animals that showed signs of barotrauma, never restraining therapy. The etiologies with the highest prescription were neurological (n = 29), traumatic (n = 14) and metabolic (n = 7), with best results shown after elevated ATA treatments, resulting on 64% (32/50) of the patients treated with ATA higher than 2,0. It was also proven that the average of ATA values presented a statistical significance tendency in relation to age (p = 0,087).
Hyperbaric oxygen therapy (HBOT) consists of inhaling a high dose (100%) of oxygen under hyperbaric conditions, that is, inside a hyperbaric chamber and subject to a pressure greater than 1.4 ATA (6psi), knowing that till values of 3.0 ATA (29.4psi) is considered a safe therapy. The main objective of this study was to identify whether HBOT causes side effects in the patient and which ones. Thus, the minor and major side effects experienced during this therapy. This study also intended to record which etiologies had the highest and lowest prescription for hyperbaric oxygen therapy and to find guidelines for the treatment of these etiologies. To this end, a population sample of 50 patients (44 dogs and 6 cats) who underwent HBOT at the Centro de Reabilitação e Regeneração Animal de Lisboa was used. The results obtained revealed that HBOT is a well-accepted therapy for all patients and that the side effects observed never prevent it from being performed. It was also observed that the etiologies with the highest prescription are those of neurological, traumatic and metabolic origin, and that all benefit more from the use of elevated ATA. The results obtained revealed that HBOT is a well-accepted therapy for all patients, with 76% of them showing acceptance for the chamber. Regarding minor side effects (ESm), the highest percentages (42%) are related to yawning, swallowing and head shaking. The major side effects were limited to 2% of the animals that showed signs of barotrauma, never restraining therapy. The etiologies with the highest prescription were neurological (n = 29), traumatic (n = 14) and metabolic (n = 7), with best results shown after elevated ATA treatments, resulting on 64% (32/50) of the patients treated with ATA higher than 2,0. It was also proven that the average of ATA values presented a statistical significance tendency in relation to age (p = 0,087).
Descrição
Orientação : Ana Maria Duque de Araújo Munhoz ; Ângela Paula Neves Rocha Martins
Palavras-chave
MESTRADO INTEGRADO EM MEDICINA VETERINÁRIA, VETERINÁRIA, MEDICINA VETERINÁRIA, OXIGENOTERAPIA, CÃES, GATOS, MEDICINA HIPERBÁRICA, OXIGÉNIO, EFEITOS SECUNDÁRIOS, PORTUGAL, VETERINARY MEDICINE, OXYGEN INHALATION THERAPY, DOGS, CATS, HYPERBARIC MEDICINE, OXYGEN, SIDE EFFECTS, PORTUGAL